Overview
- Gallup reports a statistically meaningful fall in adult obesity to 37% in 2025, down from the 2022 peak of 39.9%, representing about 7.6 million fewer obese adults.
- The share of adults who say they have taken injectable GLP-1 drugs for weight loss more than doubled to 12.4% since February 2024, aligning with the decline in obesity.
- Diabetes diagnoses reached a record 13.8% this year, a reminder that short-term reductions in obesity do not immediately lower the share of people living with a lifelong disease.
- Women and adults ages 40–64 saw the largest obesity declines, matching the groups with the highest reported use of GLP-1 medications.
- Access remains constrained by cost and coverage decisions, with many plans not covering newer drugs such as Zepbound, CVS Caremark favoring Wegovy on formularies, and typical out-of-pocket costs near $500 a month without insurance.